Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study

被引:13
|
作者
Rogler, Anja [1 ]
Hoja, Sabine [1 ]
Giedl, Johannes [1 ]
Ekici, Arif B. [2 ]
Wach, Sven [3 ]
Taubert, Helge [3 ]
Goebell, Peter J. [3 ]
Wullich, Bernd [3 ]
Stoeckle, Michael [4 ]
Lehmann, Jan [5 ]
Petsch, Sabrina [6 ]
Hartmann, Arndt [1 ]
Stoehr, Robert [1 ]
机构
[1] Univ Hosp Erlangen, Inst Pathol, D-91054 Erlangen, Germany
[2] Univ Erlangen Nurnberg, Inst Human Genet, D-91054 Erlangen, Germany
[3] Univ Hosp Erlangen, Dept Urol, D-91054 Erlangen, Germany
[4] Univ Hosp Saarland, Clin Urol & Childrens Urol, D-66421 Homburg, Saar, Germany
[5] Urol Practice Pruner Gang, D-24105 Kiel, Germany
[6] Univ Erlangen Nurnberg, Tumour Zentrum, D-91052 Erlangen, Germany
来源
BMC CANCER | 2014年 / 14卷
关键词
MTUS1; ATIP; Bladder cancer; Chromosome 8p deletions; TRANSITIONAL-CELL-CARCINOMA; RECEPTOR-INTERACTING PROTEINS; POOR-PROGNOSIS; PROSTATE-CANCER; URINARY-BLADDER; CHROMOSOME; 8P; CULTURE MODEL; LINES; PROGRESSION; GENES;
D O I
10.1186/1471-2407-14-214
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Seventy percent of all bladder tumours tend to recur and need intensive surveillance, and a subset of tumours progress to muscle-invasive and metastatic disease. However, it is still difficult to find the adequate treatment for every individual patient as it is a very heterogeneous disease and reliable biomarkers are still missing. In our study we searched for new target genes in the critical chromosomal region 8p and investigated the potential tumour suppressor gene candidate MTUS1/ATIP in bladder cancer. Methods: MTUS1 was identified to be the most promising deleted target gene at 8p in aCGH analysis with 19 papillary bladder tumours. A correlation with bladder cancer was further validated using immunohistochemistry of 85 papillary and 236 advanced bladder tumours and in functional experiments. Kaplan-Meier analysis and multivariate Cox-regression addressed overall survival (OS) and disease-specific survival (DSS) as a function of MTUS1/ATIP expression. Bivariate correlations investigated associations between MTUS1/ATIP expression, patient characteristics and histopathology. MTUS1 expression was analysed in cell lines and overexpressed in RT112, where impact on viability, proliferation and migration was measured. Results: MTUS1 protein expression was lost in almost 50% of all papillary and advanced bladder cancers. Survival, however, was only influenced in advanced carcinomas, where loss of MTUS1 was associated with adverse OS and DSS. In this cohort, there was also a significant correlation of MTUS1 expression and histological subtype: positive expression was detected in all micropapillary tumours and aberrant nuclear staining was detected in a subset of plasmocytoid urothelial carcinomas. MTUS1 was expressed in all investigated bladder cell lines and overexpression in RT112 led to significantly decreased viability. Conclusions: MTUS1 is a tumour suppressor gene in cultured bladder cancer cells and in advanced bladder tumours. It might represent one new target gene at chromosome 8p and can be used as an independent prognostic factor for advanced bladder cancer patients. The limitation of the study is the retrospective data analysis. Thus, findings should be validated with a prospective advanced bladder tumour cohort.
引用
收藏
页数:14
相关论文
共 34 条
  • [31] KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China
    Li, Qianni
    Zhou, Qi
    Zhao, Shicai
    Wu, Peng
    Shi, Ping
    Zeng, Jia
    Xiong, Xiaomin
    Chen, Haiwen
    Kittaneh, Muaiad
    Bravaccini, Sara
    Zanoni, Michele
    Zhou, Chengzhi
    Zhang, Jiexia
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (10) : 2136 - 2147
  • [32] Effect of the thyroid transcription factor 1 expression and treatment discontinuation due to adverse events on progression-free survival in patients with advanced non-squamous non-small cell lung cancer treated with pembrolizumab plus pemetrexed and platinum chemotherapy: a Japanese four-hospital, retrospective study
    Mori, Shoma
    Maiguma, Takayoshi
    Yoshii, Keisuke
    Moriya, Yasushi
    Takada, Ryo
    Shinkai, Fumitaka
    Haruki, Yuto
    Hashimoto, Hikari
    Komoto, Atsushi
    Takayanagi, Kazunobu
    Tamura, Koji
    Okura, Yusuke
    Sugiyama, Tetsuhiro
    Shimada, Kenichi
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (08):
  • [33] High PD-L1 expression on immune cells along with increased density of tumor-infiltrating lymphocytes predicts a favorable survival outcome for patients with loco-regionally advanced head and neck cancer: early results from a prospective study
    Blazek, Tomas
    Petras, Marek
    Hurnik, Pavel
    Matousek, Petr
    Knybel, Lukas
    Cermakova, Zuzana Zdeblova
    Stembirek, Jan
    Cvek, Jakub
    Soumarova, Renata
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [34] Neither germinal center (GC) vs non-germinal center (non-GC) phenotype nor FOXP1 expression correlate with outcome in AIDS-associated diffuse large B-cell lymphoma (DLBCL): Study of patients from AIDS malignancies consortium trials 010 and 034.
    Chadburn, Amy
    Chen, Xia
    Chiu, April
    Hyjek, Elizabeth
    Tam, Wayne
    Kaplan, Lawrence
    Scadden, David T.
    Knowles, Daniel M.
    Cesarman, Ethel
    BLOOD, 2006, 108 (11) : 573A - 573A